An analysis published in Open Forum Infectious Diseases found a 56% reduced risk of mortality for COVID-19 patients taking the anti-parasitic drug ivermectin compared to standard of care or another therapy. The study pulled data from 24 randomized trials involving 3,328 patients with moderate to severe COVID-19. The study also found that ivermectin was “associated…
Antibiotic azithromycin shows no benefit in severe COVID-19 trial
Commonly used to treat bacterial infections ranging from pink eye to pneumonia, the antibiotic azithromycin emerged as an early candidate for treating bacterial co-infections tied to SARS-CoV-2. But a recent clinical trial of the common antibiotic found that the drug is not an effective therapy for hospitalized COVID-19 patients. The U.K.-based RECOVERY trial had previously…
Study: Hydroxychloroquine not warranted for hospitalized COVID-19 patients
A National Institutes of Health clinical trial has concluded that hydroxychloroquine had no clinical benefit for hospitalized COVID-19 patients. The Journal of the American Medical Association published the results from the blinded, placebo-controlled, randomized trial. The clinical trial, known as the “ORCHID” study, treated 479 symptomatic COVID-19 patients with hydroxychloroquine in 34 hospitals in the…